The Community Oncology Alliance released the COA Prescription for Health Care Reform, a blueprint that diagnoses the fundamental challenges facing the U.S. healthcare system, outlines the consequences for patients across America, and presents “actionable solutions .”
Biologic drugs play an important role in treating cancers such as breast cancer and lymphoma, but their high costs can add to the financial burden of cancer care. Now, lower-cost versions known as biosimilars are gaining ground, and a study led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center suggests their growing use is associated with lower costs for both insurers and patients.
